Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The drug is priced at Rs 2000 for a course of 40 tablets
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
It is estimated that one-third of our country’s population has some form of these disorders
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Early detection of breast cancer increases survival rate by 95 per cent
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
Subscribe To Our Newsletter & Stay Updated